The Viatris Pacira deal is official: Viatris will buy Pacira BioSciences for $36.50 per share in cash, about $1.65 billion in equity value. That is a hefty check for a company that, until now, mostly sold you the generic version of things.
According to the company announcement, both boards approved the deal unanimously. Pacira’s board is also urging its shareholders to take the money. The price works out to a 44.8% premium over Pacira’s last close, Reuters reported.
How the tender offer works
This is a tender offer, not a drawn-out shareholder vote. A Viatris subsidiary will launch the offer. The offer stays open for 10 business days, though Viatris can extend it. There is no financing condition, according to Viatris’s SEC filing.
Once the offer closes, the subsidiary merges into Pacira. Pacira then becomes a wholly owned Viatris unit, and Nasdaq delists its stock. Holders must tender a majority of Pacira shares, and the regulatory waiting period has to expire first. The companies expect the deal to close by the end of 2026.
One catch: the tender offer has not formally started yet. Viatris has not disclosed a start or expiration date, so the clock has not begun ticking.
What Viatris is buying in the Pacira BioSciences takeover
Pacira sells two products. EXPAREL is a long-acting injectable used for postsurgical pain. ZILRETTA is an extended-release injection for osteoarthritis knee pain. The company also has a musculoskeletal pipeline, including a Phase 2 gene therapy candidate for knee osteoarthritis.
The financial picture is solid. Pacira posted about $746 million in revenue and about $177 million in adjusted EBITDA over the 12 months ended June 30, 2026. Pacira also says it has helped nearly 20 million patients access non-opioid pain therapies.
Viatris CEO Scott A. Smith called the deal “an important step in advancing our strategy to build our innovative medicines business.” He also said it is “synergistic with our fast-acting meloxicam market opportunity” and positions Viatris as “a leader in non-opioid pain management therapies.” Pacira said it is confident Viatris’s “shared vision, substantial resources, and global scale” will help bring its therapies to more patients.
Why generics giant Viatris wants brands
Viatris built its name on generics. Generics are a tough game. Prices keep falling, rivals keep multiplying, and the margins get thinner every year. Branded, patent-protected drugs are where the money lives.
That is the pivot here. The company has also had a rough stretch operationally, with manufacturing setbacks in India, including a fire at its Nashik plant, plus growing generic competition. Viatris buying Pacira, with its real brands and real revenue, is a way to change the story. It is also the kind of big, strategy-shifting bet we saw when Paramount and Warner Bros. folded into Skydance, only in pharma.
It is also a bet on where pain care is heading. Doctors and patients want options that don’t involve opioids, and the companies behind those options are suddenly very attractive. In that light, the Viatris Pacira acquisition looks less like an impulse buy and more like a calculated repositioning.
Pacira’s investors had little to cheer about before this. The stock had lost 15% over the prior three years, per the Motley Fool. The shares jumped on the news.
Paying for the Viatris Pacira merger and what comes next
Viatris says it will fund the purchase mainly with excess cash, with the rest coming from short-term borrowings. It expects a minimal impact on its gross leverage ratio. Interim CFO Paul Campbell said the deal should be “immediately accretive to our financial guidance metrics.” Big corporate bets like this often lean on financing, as in SpaceX’s $40B chip debt push, but Viatris is mostly writing a check from its own cash.
Next, Viatris files its tender offer paperwork and the 10-day window opens. The other date to circle is Dec. 27. That is when the FDA is expected to decide on Viatris’s fast-acting meloxicam for moderate-to-severe acute pain. Smith says that drug fits neatly alongside Pacira’s lineup.
So the real question isn’t whether Viatris can afford Pacira. It’s whether a generics giant can learn to sell brands before the pain-relief market moves on without it. Whatever the answer, the Viatris Pacira deal is now the test case.
